Feasibility Studies: Where Medical Device Clinical Programs Quietly Succeed — or Fail

I often hear early-stage device companies say, “We want to move fast and start with a large clinical study.” Speed feels like progress, especially when funding and timelines are tight.

But here’s the hard truth: moving fast without the right clinical foundation often slows programs down later.

FDA expectations don’t disappear just because a study is early or small. Feasibility studies, including early feasibility and first-in-human work, are still expected to be scientifically sound, ethically conducted, well documented, and aligned with the intended regulatory pathway.

In many cases, a well-designed feasibility study is actually the faster path forward. It allows teams to answer critical questions, refine the device and protocol, and reduce downstream risk before committing to a larger, more expensive trial.

When feasibility studies are skipped or under-designed, the outcome isn’t speed. It’s unusable data, delayed development, and costly rework.

The smartest teams treat feasibility as a strategic investment, not a checkbox. Small studies still require big thinking.

For anyone planning early clinical work, the U.S. Food and Drug Administration Early Feasibility Studies (EFS) Program is essential reading:
https://www.fda.gov/medical-devices/investigational-device-exemption-ide/early-feasibility-studies-efs-program